1.	Phase III Chemohormonal Therapy with ADR/CCNU/VCR/FXM vs CTX/MPA plus Immunotherapy with C. parvum for Metastatic Renal Carcinoma Phase: Phase III Type: Treatment Status: Closed Age: 20 to 70 Sponsor: Protocol IDs: MSHMC-REN-2
2.	CACP/HMM vs CACP/HMM/MPA for Advanced Epithelial Ovarian Tumor - A Phase III Study Phase: Phase III Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: NCI-D79-019-073, BUCRC-751
3.	Phase III Randomized Study of Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women With a History of Node-Negative Invasive Carcinoma or Ductal Carcinoma in Situ of the Breast Who are Receiving Adjuvant Tamoxifen Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: E-2193, NCI-P01-0194, NCT00026286, ECOG-E2193
4.	Phase III Randomized Study of Medroxyprogesterone Versus Venlafaxine in Women With Symptomatic Hot Flashes Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N99C7, NCI-P02-0204, NCT00030914
5.	Phase III Percutaneous Transfemoral Renal Artery Occlusion, Nephrectomy and Hormonal Therapy with Medroxyprogesterone Acetate for Metastatic Renal Carcinoma Phase: Phase III Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: MDA-U/u17
6.	Phase III Provera (MPA) vs ADR vs ADR/CTX for Stage III/IV or Recurrent Endometrial Cancer Phase: Phase III Type: Treatment Status: Closed Age: no age specified Sponsor: NCI Protocol IDs: GOG-48, GOG-7941
7.	Phase III Postinfarction Nephrectomy plus Medroxyprogesterone Acetate for Metastatic Renal Cell Carcinoma Phase: Phase III Type: Treatment Status: Closed Age: no age specified Sponsor: NCI Protocol IDs: SWOG-7956
8.	Phase III Comparison of Immuneron vs Depo-Provera in Patients with Metastatic Renal Cell Carcinoma Phase: Phase III Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Protocol IDs: BGSM-89285, NCI-V85-0243
9.	Phase III Randomized Trial of Adjuvant Therapy with Medroxyprogesterone Acetate in Patients with High-Risk Endometrial Cancer (Summary Last Modified 08/89) Phase: Phase III Type: Treatment Status: Closed Age: any age Sponsor: Protocol IDs: COSA-UK-NZ-E1/82
10.	Phase III Evaluation of High-dose vs Low-dose Medroxyprogesterone Acetate for Advanced Stage III/IV Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: EORTC-10802
11.	Phase III Randomized Study of Hormonal Therapy with TMX vs High-Dose MPA in Adult Patients with Advanced Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: over 18 Sponsor: Protocol IDs: POA-74185
12.	Master Protocol for Hormonal Treatment of Advanced or Recurrent Endometrial Carcinoma --- Phase III Medroxyprogesterone Acetate for Patients with Positive Estrogen and Progesterone Receptors Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: GOG-81B
13.	Master Protocol for Hormonal Treatment of Advanced or Recurrent Endometrial Carcinoma --- Phase III Medroxyprogesterone Acetate for Patients with Negative Estrogen and Progesterone Receptors Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: GOG-81C
14.	Master Protocol for Hormonal Treatment of Advanced or Recurrent Endometrial Carcinoma --- Phase III Medroxyprogesterone Acetate for Patients with Either Positive Estrogen or Positive Progesterone Receptors Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: GOG-81D
15.	Master Protocol for Hormonal Treatment of Advanced or Recurrent Endometrial Carcinoma --- Phase III Medroxyprogesterone Acetate for Patients with Unknown Estrogen and Progesterone Receptors Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: GOG-81E
16.	Phase III Randomized Comparison of Continuous vs Intermittent TMX vs Alternating TMX and MPA as First-Line Endocrine Therapy for Postmenopausal Patients with Advanced Carcinoma of the Breast Phase: Phase III Type: Treatment Status: Closed Age: postmenopausal Sponsor: Protocol IDs: EORTC-10863
17.	Phase III Randomized Study of Low-Dose vs High-Dose Medroxyprogesterone Acetate (Provera) in Patients with Advanced, Persistent, or Recurrent Endometrial Carcinoma Phase: Phase III Type: Treatment Status: Closed Age: no age specified Sponsor: NCI Protocol IDs: GOG-81
18.	Phase III Randomized Study of MPA with or without Continuation of Tamoxifen in Postmenopausal Patients with Advanced Breast Cancer that is Progressive on Tamoxifen (Summary Last Modified 09/90) Phase: Phase III Type: Treatment Status: Closed Age: postmenopausal Sponsor: Protocol IDs: COSA-ANZ-8613
19.	Phase III Randomized Trial of a Loading Dose of MPA vs No Loading Dose with Two Different Schedules of MPA Maintenance in Women with Advanced Breast Cancer (Summary Last Modified 07/91) Phase: Phase III Type: Treatment Status: Closed Age: pre/postmenopausal Sponsor: Protocol IDs: CRC-TU-BR3007, EU-90036
20.	Phase III Randomized Trial of IFN-A vs MPA in Patients with Metastatic Renal Carcinoma (Summary Last Modified 07/98) Phase: Phase III Type: Treatment Status: Closed Age: any age Sponsor: Protocol IDs: MRC-RE01, EU-91021
21.	Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CDR0000468571, LEONB-PERCY-QUATTRO, EU-20605, LEONB-ET99-058, ROCHE-LEONB-PERCY-QUATTRO, CHIRON-LEONB-PERCY-QUATTRO, NCT00416429
22.	S9630, Medroxyprogesterone in Treating Women With Breast Cancer Phase: Phase III Type: Prevention, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000065314, CALGB-49901, S9630, U10CA037429, U10CA032102, SWOG-S9630, SWOG-9630, NCT00002920
23.	Prospective Study of Immediate Hysterectomy and Phase II Randomized Study of Medroxyprogesterone Acetate (Provera) Versus Medroxyprogesterone Acetate Suspension (Depo-Provera) Prior to Hysterectomy in Patients With Atypical Endometrial Hyperplasia Phase: Phase II Type: Prevention Status: Completed Age: Not specified Sponsor: NCI Protocol IDs: GOG-0167, NCT00003179
24.	Phase II Chemotherapy with VBL/CCNU/HU and Hormone Therapy with Medroxyprogesterone Acetate for Metastatic Renal Adenocarcinoma Phase: Phase II Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: SEG-GU-P33
25.	Hormone Therapy in Preventing Endometrial Carcinogenesis (Cancer) in Women With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer Phase: Phase II Type: Prevention Status: Closed Age: 25 to 50 Sponsor: NCI, Other Protocol IDs: ID01-340, P30CA016672, MDA-ID-01340, NCI-P02-0218, CDR0000069277, TX035, N01-CN-05127, NCT00033358